Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
The pharmaceutical and biotechnology business tends to be about hitting home runs more than just getting on base. A highly successful drug, sometimes referred to as a blockbuster, can build up a small developer into a mainstream competitor. That's what investors are hoping for from Viking Therapeutics (NASDAQ: VKTX), a young company seeking to establish itself in this highly competitive industry.
Viking stock has been extraordinarily volatile since it went public a decade ago. The stock has traded as low as under $1 per share and as high as $94 at its peak.
While the company's future remains uncertain, significant business developments are forthcoming that could affect the stock's performance over the next three years. Here's what you need to know about investing in Viking Therapeutics today.
